Credits: Canva
As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.
As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."
The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.
The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.
Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.
As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.
A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.
TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."
Credit: AI image
Speech is “really a window into brain health”, said Dr. Marilu Gorno Tempini, director of the language neurobiology laboratory at the University of California, San Francisco. The neuroscientist used the phrase while talking about developments in research related to changes in speed and dementia risk.
Described as one of the most “fascinating fields of research” by billionaire tech entrepreneur Bill Gates, speech patterns, including pauses while speaking, speaking speed, choice of words, vocabulary and sentence structure, are being studied to identify early changes in brain health.
Speech is a complex brain activity, which entails processing language, vocabulary, retrieving memories, focusing and paying attention. Changes in any of these activities could indicate a person’s cognitive decline and their risk of developing neurodegenerative disorders like Alzheimer’s.
Technological advances in artificial intelligence have made it possible to analyse speech patterns that could be recorded in everyday communications.
Also read: Experimental Alzheimer's Drug Slows Cognitive Decline By 38% In A Two-Year Trial: How Does It Work?
Due to developments in the field, it has become feasible for researchers to analyse speech-related changes that reflect cognitive health.
People can record themselves, producing useful data that can be combined with brain imaging and blood tests, could be used to predict dementia risk and monitor progression of cognitive impairment.
Marziye Eshghi from Mass General Brigham University of Health Professions in Boston is leading the research in the area. She said, “We are seeing differences that humans can’t see or can’t really detect by their ears, but it’s there years and years before cognitive decline.”
Dr. Eshghi’s project is based on 130 different speech-related features in participants. The data is then processed through artificial intelligence algorithms and compared to established biological risk factors for Alzheimer’s disease.
After the preliminary results came out, it was observed that speech-related data was better than cognitive testing at identifying Alzheimer’s risk in cognitively unimpaired older people.
“What we are doing is capturing individuals who are at higher risk of developing Alzheimer’s disease, but they are still not showing any symptoms,” said Dr. Eshghi.
Speech analysis could also help researchers determine those at greater risk among people who have tested positive for Alzheimer’s biomarkers, Melissa Lee, who directs digital and A.I. at the nonprofit Alzheimer’s Drug Discovery Foundation, told New York Times.
She said, “If we have two people with positive blood tests, one shows decline and one won’t, and we’d use their speech to tell them apart.”
Also read: Can Unhappy Marriages Increase Dementia Risk? Study Finds 38% Chance
In one of the studies, 49 people without cognitive impairment were classified as low-risk, moderate-risk or high-risk based on levels of an Alzheimer’s-related protein in their blood and whether they had a genetic variant commonly observed with increased risk.
Researchers then analyzed speech recordings, without knowing participants’ risk categories, and tested whether a computer model could determine which participants were in which group.
In preliminary results, the speech-based analysis classified participants accurately up to 77 percent of the time. This fared much better than the 47 percent accuracy of common cognitive testing models.
Changes in speech pattern may also be used in analysing other health conditions like depression, Parkinson’s disease, and diabetes. These three conditions are often accompanied with subtle changes in voice like talking speed, slurred speech, and vocal hoarseness.
Credit: AI image
India has administered more than 1 crore doses of the human papillomavirus (HPV) vaccine in less than nine months since it launched its nationwide vaccination campaign.
This means the country has covered nearly 87% of its annual target cohort of 14-year-old girls. The milestone marks a major step towards preventing cervical cancer, which is largely caused by repeated HPV infections.
According to the Ministry of Health and Family Welfare, the campaign has reached nearly 87% of its estimated annual target of 1.2 crore girls, based on 2021 population estimates from the Registrar General of India.
The vaccination drive was started in February 2026 and provides free, voluntary single-dose HPV vaccination to eligible 14-year-old girls at designated government health facilities.
Six states, Gujarat, Uttar Pradesh, Andhra Pradesh, Mizoram, Madhya Pradesh and Bihar, have reported 100% coverage of their target populations.
Among other states, Assam has recorded 95.63% coverage, followed by Telangana at 95.28%, Karnataka at 93.16% and Uttarakhand at 90.17%. Chhattisgarh and Rajasthan have crossed 80% coverage, while Kerala, Tamil Nadu and Odisha have achieved more than 70%.
In terms of the number of girls vaccinated, Uttar Pradesh leads with more than 29.33 lakh, followed by Bihar with 13.70 lakh and Gujarat with 7.75 lakh.
Also read: Menstrual Blood-Based Self-Sampling Cervical Cancer Test Gets Patent-Know Everything About It
Almost all cervical cancer cases are caused by repeated infection with high-risk types of human papillomavirus, a common virus transmitted through sexual contact.
Most HPV infections clear naturally without causing health problems. The progression from HPV infection to cervical cancer generally takes 15–20 years, but it can happen faster in women with weakened immune systems.
HPV vaccination helps prevent infections caused by HPV types that cause cancer before exposure to the virus. Vaccinating girls at age 14 aims to provide protection before they are likely to encounter HPV. The vaccine is a preventive intervention. It does not treat an existing HPV infection or cervical cancer.
Also read: About 7.9% Of Women In Kerala Are Affected By Cervical Cancer; Why Early Detection Is Important
The government says the campaign's progress has been supported by coordination between the Centre, state governments, district administrations, healthcare professionals and frontline workers, including ASHAs and ANMs.
The U-WIN digital platform is being used for beneficiary tracking, monitoring vaccination coverage, maintaining digital records and identifying eligible girls yet to receive the vaccine. Parents can also use the platform to book vaccination slots and obtain digital certificates.
Vaccination sessions are conducted at designated government health facilities under the supervision of trained medical officers. Arrangements have also been made for identifying and managing adverse events after vaccination.
Cervical cancer remains a major public health concern in India, despite being largely preventable through HPV vaccination.
The World Health Organization's cervical cancer elimination strategy aims for 90% of girls to be fully vaccinated against HPV by age 15, 70% of women to undergo screening by ages 35 and 45, and 90% of women diagnosed with cervical disease to receive appropriate treatment.
Cervical cancer prevention entails HPV vaccination, regular screening and timely treatment of precancerous changes.
Credit: AI image
In what can be described as a major breakthrough, a new treatment combination has shown tremendous promise in advanced pancreatic cancer treatment. A recent early-stage clinical trial showed that the combo shrank tumours in more than 60% of patients and controlled disease progression in 90% of patients.
The findings raise hope for pancreatic cancer, which is often diagnosed late as well as has limited treatment options. Despite positive outcomes, larger trials are needed to establish how much the treatment improves survival.
Also read: Experimental Vaccine For Blood Cancer Cuts Death Risk By 41% In Trial: How Does It Work?
The combination includes daraxonrasib, an experimental targeted cancer drug, alongside two chemotherapy medicines, gemcitabine and nab-paclitaxel.
The updated results from the Phase 1/2 RMC-GI-102 trial were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.
The study involved 61 patients with metastatic pancreatic adenocarcinoma who had not previously received treatment for their metastatic disease. Participants received the combination and were followed for a median of 18.3 months.
A 90.2% control in disease was reported, meaning the cancer either shrank or remained stable. The objective response rate, which measures tumours that shrank significantly or disappeared, was 60.7%. This included complete responses in 8.2% of patients, whose tumours were no longer detected.
Median progression-free survival was 12.8 months, meaning patients lived a median of nearly 13 months without their cancer progressing or dying. The estimated proportion of patients alive at one year was 76.6%.
Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who presented the findings, said “this is the closest to cure”. He also said that he had never seen so many tumours disappear in patients whose cancer had spread.
He also said, “We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival."
He added, “The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission … it’s incredible.”
Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer
Daraxonrasib, also known as RASONQUE, targets RAS, which drives cell growth. Mutations in RAS, especially KRAS, can keep these growth signals on, allowing pancreatic cancer cells to multiply uncontrollably.
The drug is designed to inhibit active RAS proteins and disrupt the signals that cancer cells depend on for growth and survival. Researchers are combining it with chemotherapy to attack the cancer through different mechanisms.
Gemcitabine interferes with cancer cell DNA synthesis, while nab-paclitaxel disrupts microtubules, structures essential for cell division. Combining these drugs with targeted RAS inhibition could produce more sustained responses.
Pancreatic cancer remains one of the most difficult cancers to treat once it has spread beyond the pancreas. Many patients are diagnosed at an advanced stage, when surgery may no longer be possible.
The RAS signalling mechanism has long been considered a challenging target for cancer treatment. The development of drugs capable of fighting this has therefore opened a new avenue of research, especially pancreatic cancers driven by RAS mutations.
The trial's response rates and duration of disease control are encouraging. However, it was a small, open-label study without a chemotherapy comparison group.
Researchers cannot determine yet how much of the benefit came from daraxonrasib rather than chemotherapy or whether the combination will significantly extend survival.
Daraxonrasib is being investigated in larger clinical trials to determine its effectiveness and safety. A Phase 3 trial, RASolute 303, is comparing daraxonrasib alone, daraxonrasib combined with gemcitabine and nab-paclitaxel, and chemotherapy alone in patients with previously untreated metastatic pancreatic cancer.
These results will help establish whether the promising early findings translate into a meaningful improvement in survival and whether the combination could become a new treatment option.
© $2026 Times Horizon Private Limited